Evidence map›Paper›PMID 35352511›Full record

ReviewClinical and translational medicine2022

Single-cell RNA sequencing technologies and applications: A brief overview.

Dragomirka Jovic, Xue Liang, Hua Zeng, Lin Lin, Fengping Xu, Yonglun Luo

Open access · goldAbstract readReview
In one paragraph

Review in Clinical and translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 730 papers.

0numbers the graph read from it
0cells of the map it votes in
730citing papers in PubMed
97.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

730 citing papers in PubMed, 1,181 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Integration of Bulk RNA Sequencing and Single-Cell Sequencing to Identify Prognostic Genes Associated With MCDRGs in Neuroblastoma.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

670 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Dragomirka JovicLars Bolund Institute of Regenerative Medicine, Qingdao-Europe Advanced Institute for Life Sciences, Qingdao, China.
Xue LiangLars Bolund Institute of Regenerative Medicine, Qingdao-Europe Advanced Institute for Life Sciences, Qingdao, China.
Hua ZengNanjing University of Chinese Medicine, Nanjing, China.
Lin LinDepartment of Biomedicine, Aarhus University, Aarhus, Denmark.
Fengping XuLars Bolund Institute of Regenerative Medicine, Qingdao-Europe Advanced Institute for Life Sciences, Qingdao, China.
Yonglun LuoLars Bolund Institute of Regenerative Medicine, Qingdao-Europe Advanced Institute for Life Sciences, Qingdao, China.ORCID 0000-0002-0007-7759
BGI Group (China) · CNNanjing University of Chinese Medicine · CNSteno Diabetes Centers · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Single-cell RNA sequencing (scRNA-seq) technology has become the state-of-the-art approach for unravelling the heterogeneity and complexity of RNA transcripts within individual cells, as well as revealing the composition of different cell types and functions within highly organized tissues/organs/organisms. Since its first discovery in 2009, studies based on scRNA-seq provide massive information across different fields making exciting new discoveries in better understanding the composition and interaction of cells within humans, model animals and plants. In this review, we provide a concise overview about the scRNA-seq technology, experimental and computational procedures for transforming the biological and molecular processes into computational and statistical data. We also provide an explanation of the key technological steps in implementing the technology. We highlight a few examples on how scRNA-seq can provide unique information for better understanding health and diseases. One important application of the scRNA-seq technology is to build a better and high-resolution catalogue of cells in all living organism, commonly known as atlas, which is key resource to better understand and provide a solution in treating diseases. While great promises have been demonstrated with the technology in all areas, we further highlight a few remaining challenges to be overcome and its great potentials in transforming current protocols in disease diagnosis and treatment.

Indexed as

Gene Expression ProfilingSingle-Cell AnalysisAnimalsExome SequencingSequence Analysis, RNATechnologyatlasbig dataprecision medicineregenerative medicineRNA sequencingsingle cell

Identifiers

PMID35352511
PMCPMC8964935
OpenAlexW4220837089

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.